

1:15 p.m. – 2:45 p.m.

Selected Paper Session #3

Moderator: Sue W. Goldstein, BA

- 1:15 p.m. #17 **PRIZE ESSAY WINNER: PSYCHOLOGY-CLINICAL:**
BEHAVIOR AND SYMPTOM CHANGE AMONG WOMEN TREATED WITH PLACEBO FOR SEXUAL DYSFUNCTION
Andrea Bradford¹ and Cindy Meston²
¹Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX; ²Department of Psychology, University of Texas, Austin, TX
(Presented By: Andrea Bradford)
- 1:28 p.m. #18 **GEPIRONE-ER TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN WOMEN WITH MAJOR DEPRESSION**
Leonard Derogatis
Sheppard Pratt Hospital, Center for Sexual Medicine
(Presented By: Leonard Derogatis)
- 1:39 p.m. #19 **LOW CARDIOVASCULAR EVENT RATE IN POST-MENOPAUSAL WOMEN WITH INCREASED CARDIAC RISK: FINDINGS FROM THE BLINDED ONGOING LIBIGEL® (TESTOSTERONE GEL) CARDIOVASCULAR AND BREAST CANCER SAFETY STUDY***
Michael Snabes¹, Jason Connor², Donald Berry³, Joanne Zborowski¹ and William White⁴
¹BioSante Pharmaceuticals, Inc., Lincolnshire, IL; ²Berry Consultants, College Station, TX; ³MD Anderson Cancer Center, Houston, TX; ⁴University of Connecticut School of Medicine, Farmington, CT
(Presented By: Michael Snabes)
**Not CME Accredited*
- 1:50 p.m. #20 **EFFICACY OF FLIBANSERIN 100 MG QHS AS A POTENTIAL TREATMENT FOR HYPOACTIVE SEXUAL DESIRE DISORDER IN PREMENOPAUSAL WOMEN**
Elaine Jolly¹, Anita Clayton², John Thorp³, Rossella Nappi⁴, Toshio Kimura⁵, Michael Sand⁵ and Robert Pyke⁵
¹Shirley E. Greenberg Women's Health Centre, The Ottawa Hospital, Ottawa, ON, Canada; ²University of Virginia, Charlottesville, VA; ³University of North Carolina at Chapel Hill, NC; ⁴University of Pavia, Italy; ⁵Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT
(Presented By: Elaine Jolly)
- 2:01 p.m. #21 **SAFETY AND TOLERABILITY OF FLIBANSERIN IN PREMENOPAUSAL WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER**
Elaine Jolly¹, Anita Clayton², John Thorp³, Rossella Nappi⁴, Toshio Kimura⁵, Vladimir Haynes⁵ and Robert Pyke⁵
¹Shirley E. Greenberg Women's Health Centre, The Ottawa Hospital, Ottawa, ON, Canada; ²University of Virginia, Charlottesville, VA; ³University of North Carolina at Chapel Hill, NC; ⁴University of Pavia, Italy; ⁵Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT
(Presented By: Elaine Jolly)

- 2:12 p.m. #22 THERE IS A CURVILINEAR RELATIONSHIP BETWEEN SNS ACTIVATION AND WOMEN'S PHYSIOLOGICAL SEXUAL AROUSAL**
Tierney Ahrold, Christopher Harte, Lisa Dawn Hamilton and Cindy Meston
University of Texas at Austin, Austin, TX
(Presented By: Tierney Ahrold)
- 2:23 p.m. #23 BASELINE CHARACTERISTICS OF WOMEN ENROLLED IN A PROSPECTIVE STUDY OF SURGICAL CLITORAL REPAIR AFTER GENITAL MUTILATION**
Pierre Foldes¹, Beatrice Cuzin² and François Giuliano³
¹CHI Poissy/Saint-Germain-en-Laye; ²E Herriot University Hospital, Lyon, France; ³Garches University Hospital, Garches, France
(Presented By: Beatrice Cuzin)
- 2:34 p.m. #24 THE SAFETY AND TOLERABILITY OF THE TRANSDERMAL TESTOSTERONE PATCH FOR UP TO 4 YEARS IN SURGICALLY MENOPAUSAL WOMEN ON ESTROGEN/ PROGESTIN THERAPY**
Lila Nachtigall¹, Peter Casson², Johna Lucas³, Victoria Schofield³, Chad Melson³ and James Simon⁴
¹New York University School of Medicine, New York, NY; ²Fletcher Allen Health Care, Burlington, VT; ³Procter & Gamble Pharmaceuticals, Mason, OH; ⁴George Washington University School of Medicine, and Women's Health & Research Consultants, Washington, DC
(Presented By: James Simon)